We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

92 hedge funds and large institutions have $369M invested in ARS Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more call options, than puts

Call options by funds: $7.92M | Put options by funds: $3.22M

68% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 19

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

6% more capital invested

Capital invested by funds: $348M → $369M (+$21.3M)

3% more funds holding

Funds holding: 89 → 92 (+3)

1.52% more ownership

Funds ownership: 56.59% → 58.11% (+1.5%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
92
Holders Change
+3
Holders Change %
+3.37%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
31
Increased
32
Reduced
19
Closed
27
Calls
$7.92M
Puts
$3.22M
Net Calls
+$4.7M
Net Calls Change
-$191K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.62M
2
Millennium Management
Millennium Management
New York
+$6.34M
3
SCM
Sio Capital Management
New York
+$3.62M
4
Two Sigma Investments
Two Sigma Investments
New York
+$3.2M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$3.08M

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$9.44M
2
RCMNY
Rubric Capital Management (New York)
New York
-$4.55M
3
NIP
Nicholas Investment Partners
California
-$3.21M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.83M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$1.63M +$598K +89,568 +58%
Northern Trust
27
Northern Trust
Illinois
$1.55M +$1.06M +158,721 +221%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$1.52M +$40K +6,000 +3%
Citadel Advisors
29
Citadel Advisors
Florida
$1.48M +$1.17M +175,572 +392%
NCM
30
Nantahala Capital Management
Connecticut
$1.21M +$1.2M +180,097 New
LCS
31
Levin Capital Strategies
New York
$1.13M +$192K +28,723 +20%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$1.01M -$1.08M -161,594 -52%
RCAP
33
Resolute Capital Asset Partners
Colorado
$938K +$133K +20,000 +17%
TC
34
Tejara Capital
United Kingdom
$895K -$494K -74,034 -36%
Goldman Sachs
35
Goldman Sachs
New York
$825K -$490K -73,351 -37%
JF
36
Jump Financial
Illinois
$750K +$493K +73,810 +194%
N
37
Nuveen
North Carolina
$654K +$651K +97,595 New
Squarepoint
38
Squarepoint
New York
$568K +$480K +71,905 +557%
Swiss National Bank
39
Swiss National Bank
Switzerland
$551K +$549K +82,300 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$515K +$412K +61,715 +406%
Marshall Wace
41
Marshall Wace
United Kingdom
$500K +$235K +35,193 +89%
CM
42
Caption Management
Oklahoma
$492K +$490K +73,400 New
Charles Schwab
43
Charles Schwab
California
$480K +$370K +55,441 +343%
AA
44
ALPS Advisors
Colorado
$467K +$465K +69,662 New
SAM
45
Shell Asset Management
Netherlands
$438K +$436K +65,322 New
CC
46
Clearline Capital
New York
$409K +$408K +61,102 New
Morgan Stanley
47
Morgan Stanley
New York
$407K -$260K -38,927 -39%
JFG
48
Jefferies Financial Group
New York
$403K +$402K +60,190 New
EP
49
Eversept Partners
New York
$327K +$326K +48,788 New
American Century Companies
50
American Century Companies
Missouri
$311K +$48.3K +7,236 +18%
1
2
3 4 5

SPRY Hedge Fund Activity: Q2 2023 in Review

92 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2023, worth a combined $369M — up 6.1% from $348M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SPRY positions and 27 closed out — a net gain of 4 holders — while 32 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $7.62M. The largest seller was K2 Principal Fund, cutting an estimated $9.44M.

  • 92 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2023, up from 89 in Q1 2023.
  • Funds reported $369M of ARS Pharmaceuticals stock for Q2 2023, up 6.1% quarter-over-quarter.
  • 31 funds opened new ARS Pharmaceuticals positions in Q2 2023 and 27 closed out, a net change of +4 holders.
  • The largest ARS Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $7.62M added.
  • The largest ARS Pharmaceuticals seller in Q2 2023 was K2 Principal Fund, an estimated $9.44M sold.

Based on aggregated 13F filings for Q2 2023.